.png)
Company Overview
Wockhardt Limited is an Indian research-based pharmaceutical and biotechnology company engaged in the development, manufacture and marketing of pharmaceutical products, biological products and active pharmaceutical ingredients (APIs). The Wockhardt Group was founded in 1967. The company’s current global headquarters is Wockhardt Towers, Bandra Kurla Complex, Bandra East, Mumbai, Maharashtra, while its registered office is located at D-4, MIDC Chikalthana, Chhatrapati Sambhajinagar, Maharashtra. Its equity shares are listed on BSE Limited and the National Stock Exchange of India Limited.
Wockhardt describes itself as a global healthcare enterprise with activities spanning pharmaceuticals, biotechnology and healthcare services. Its principal pharmaceutical business includes research and development, manufacturing and marketing of branded and generic formulations, biological products, vaccines and APIs.
Business Segments and Products
Wockhardt's official business-vertical disclosures identify six principal areas: New Drug Discovery, Biologicals in Diabetes, Branded Pharmaceuticals, Vaccines, Contract Manufacturing and APIs.
The new-drug-discovery programme has a particular focus on novel antibiotics addressing drug-resistant bacterial infections. Wockhardt's current disclosures identify novel antibiotic programmes including EMROK, EMROK O, Miqnaf, Zaynich, Foviscu and Odrate. Zaynich (zidebactam/cefepime) has received Qualified Infectious Disease Product (QIDP) designation from the U.S. FDA and, as of the company's current disclosures, has received regulatory approval in both the United States and India.
The biologicals and diabetes business includes recombinant human insulin, insulin analogues and biosimilar or biobetter products. The company also develops insulin-delivery devices and maintains biotechnology research and manufacturing capabilities.
Its branded pharmaceutical portfolio comprises finished pharmaceutical formulations, biopharmaceuticals, branded generics, prescription products and over-the-counter products across various therapeutic areas. Wockhardt also manufactures vaccines and provides contract-manufacturing services for pharmaceutical companies.
Manufacturing and Research
Wockhardt's manufacturing network covers India, the United Kingdom, the United States and the United Arab Emirates, with additional group manufacturing operations in Ireland. The company's official manufacturing page currently identifies 15 manufacturing facilities across India, the UK, USA and UAE, producing pharmaceuticals, biopharmaceutical formulations and APIs.
The facilities manufacture multiple dosage forms, including tablets, capsules, oral liquids, topical products, sterile injectables, lyophilised products, cartridges and pre-filled syringes. Several facilities have approvals or certifications associated with regulatory authorities including the US FDA, UK MHRA, WHO-GMP, ANVISA-Brazil and other national regulators.
Wockhardt's biotechnology operations include dedicated facilities in Chhatrapati Sambhajinagar for biological drug substances and drug products. The company states that these facilities use yeast, bacterial and mammalian-cell expression systems for biotechnology manufacturing.
Business Model and Markets
Wockhardt operates an integrated research-to-commercialisation pharmaceutical model, combining drug discovery, clinical development, manufacturing, regulatory capabilities and commercial marketing. It supplies branded and generic pharmaceutical products, APIs and biological products to domestic and international markets and also provides contract-manufacturing services.
The company's official website states that its worldwide marketing presence extends to more than 30 countries across six continents. Its FY2024–25 disclosures identify significant business presence in India and Europe, with operations and subsidiaries in markets including the UK, Switzerland, Ireland, Russia, the United States and other countries.
Subsidiaries and Group Companies
The FY2024–25 consolidated disclosures identify subsidiaries and step-down subsidiaries including Wockhardt Infrastructure Development Limited, Wockhardt Medicines Limited, Wockhardt Bionova Limited, Wockhardt UK Holdings Limited, Wockhardt Bio AG, Wockhardt Europe Limited, CP Pharmaceuticals Limited, Wallis Group Limited, Pinewood Healthcare Limited, Pinewood Laboratories Limited, Wockhardt Holding Corp., Morton Grove Pharmaceuticals Inc. and Wockhardt Nigeria Limited, among others.
Corporate Philosophy and Recognition
Wockhardt's corporate credo is “Life Wins.” Its official materials describe a long-standing emphasis on research, innovation and healthcare. Earlier official annual-report material identifies “The Wockhardt Way” through nine core values: Winning, Openness, Courage, Knowledge, Humility, Ambition, Reputation, Depth and Trust.
Among its officially documented achievements, Wockhardt has developed a portfolio of novel antibiotics and has received QIDP designations from the U.S. FDA for its novel antibacterial programmes. Its current corporate disclosures also record U.S. FDA approval of Zaynich, a novel intravenous antibiotic developed by Wockhardt.
Information concerning a separately published current formal mission statement is Information not officially disclosed in the current corporate sources reviewed.
.png)